Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 145 Publications

22 Customer Reviews

  • Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  •  

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

    Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NWDsXmRTS3m2b4TvfIlkKEG|c3H5 NX:zd|AzPTBizszN NVeyVGluPDhiaB?= MnHDSG1UVw>? MmrqT4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=> NVLBd2lFOTB2OUm2OFM>
OVCA 429 MXPGeY5kfGmxbjDBd5NigQ>? NVjYVFg{OzByIH7N M1fWNFQ5KGh? Mlz1SG1UVw>? NGflcXFFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> M3nUXFExQTl7N{[2
RPMI8226 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXseoFsOTByIH7N NI\mdWs1QCCq NXjUdZl3TE2VTx?= MWrJR|UxRTNyIH7N M4jMN|EyOzB4NEi5
Dox40 M1;Vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofRNVAxKG6P MVq0PEBp MU\EUXNQ NUHs[3drUUN3ME20NEBvVQ>? MX:xNVMxPjR6OR?=
MR20 MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j6W|ExOCCwTR?= MlezOFghcA>? NYfqRmVGTE2VTx?= NIC0PZFKSzVyPUKwJI5O Ml31NVE{ODZ2OEm=
LR5 NEnWW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLoNVAxKG6P M2LXfVQ5KGh? NYLIXmg1TE2VTx?= NYr1bXhxUUN3ME2yNEBvVQ>? NX63NnY1OTF|ME[0PFk>
U266 NIDQZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDTNVAxKG6P MXK0PEBp MornSG1UVw>? MoH0TWM2OD1|IH7N MXixNVMxPjR6OR?=
IM-9 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESyfHAyODBibl2= MWO0PEBp MVXEUXNQ MX;JR|UxRTZibl2= M2LoV|EyOzB4NEi5
Hs Sultan M3\Td2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3I[5cyODBibl2= M33RSVQ5KGh? NU\GdmlQTE2VTx?= MXnJR|UxRTJyIH7N NYnBOJFWOTF|ME[0PFk>
PAM-LY2 NEjaRWFHfW6ldHnvckBCe3OjeR?= NXLiPGJxOTByIH7N NWXqZ3ZqOTJiaB?= NUK2[nd{TE2VTx?= MnnvTY5pcWKrdIOgUmYu|rqEIHHjeIl3[XSrb36= NG[y[JMyOTN3MEmxNy=>
PAM 212 NFv2U2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHmbItCOTByIH7N MmXHO|IhcA>? NIPNfW1FVVOR MWDJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NFSxfmgyOTN3MEmxNy=>
PAM-LY2 Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:xNFAhdk1? M37wXlczKGh? MoSwSG1UVw>? NVq4fXJNUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MX6xNVM2ODlzMx?=
B4B8 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfUXYV7OTByIH7N MUK3NkBp MW\EUXNQ MVTJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NH;2ZWEyOTN3MEmxNy=>
B7E3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzYWlYyODBibl2= MWG3NkBp MnvOSG1UVw>? NFGwVVZKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MVOxNVM2ODlzMx?=
UM-SCC-9 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnSSJNiOTByIH7N MmLaO|IhcA>? MXLEUXNQ NIW0c3NKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= M33TWVEyOzVyOUGz
UM-SCC-11B MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGxNFAhdk1? NVrITnpnPzJiaB?= MUDEUXNQ M4[wXmlvcGmkaYTzJINmdGxidnnhZoltcXS7 M3rEZVEyOzVyOUGz
H460 M1jVe2Z2dmO2aX;uJGF{e2G7 MWSxNEDPxE1? MojtNlQhcA>? M4H5cmROW09? NXXyZpBOUW6mdXPld{BD[2xvMjDwbI9{eGixconsZZRqd25iYX7kJINt\WG4YXflJINwenKnbHH0[YQhf2m2aDDHNk1OKHCqYYPlJIFzemW|dB?= NEnOOnIyOjR7MkGxOy=>
U266 M1nxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\pbVUxOCCwZz;tcC=> MVu0PEBp M3fBRWROW09? NF\tV5RKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MoHzNVI3OzF4MUm=
ARH77 NYTkRYZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q0b|UxOCCwZz;tcC=> NVL4eGFpPDhiaB?= M4e1S2ROW09? MlvuTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M4O2[lEzPjNzNkG5
WAD-1 NXP0cnJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LT[FUxOCCwZz;tcC=> M1XHWlQ5KGh? MlzNSG1UVw>? MnvBTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NEHUR3kyOjZ|MU[xPS=>
U266/LR7 M4Hz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfKOW9PPTByIH7nM41t NWHoTpNbPDhiaB?= NIfoUoJFVVOR NWDY[|JEUW6qaXLpeJMh[2WubDDndo94fGh? NGm2UnQyOjZ|MU[xPS=>
U266/dox4 NFTYWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITOZXQ2ODBibnevcYw> NGHNdow1QCCq M2\Ze2ROW09? NF7zR4dKdmirYnn0d{Bk\WyuIHfyc5d1cA>? M3r1N|EzPjNzNkG5
RPMI8226/LR5 MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TwWFUxOCCwZz;tcC=> NFv1THI1QCCq M1fu[mROW09? M{TPe2lvcGmkaYTzJINmdGxiZ4Lve5Rp NUjMTpg3OTJ4M{G2NVk>
H460 NFfkZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;DeHliOTBizszN MoXyO|IhcA>? MYTEUXNQ NV:5NYI4UUN3ME2xNFAhdk1? M4\3fVEzPjNzNkKw
H358 MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP1Z5VpOTBizszN MkXiO|IhcA>? M2rVWGROW09? MVvJR|UxRTdyIH7N NILTZZoyOjZ|MU[yNC=>
H322 NGnxRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmO0NVAh|ryP NW\YXJFSPzJiaB?= M1SyfWROW09? NWLQTolpUUN3ME22NlAhdk1? NFHxd20yOjZ|MU[yNC=>
H460 Mo\JSpVv[3Srb36gRZN{[Xl? Mn3ZNVAxKG6P NH;5NpozPCCq NHzSd3BFVVOR M3niO2lv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl? M1HBTVEzPjNzNkKw
LNCap-Pro5 NF3ZRpFHfW6ldHnvckBCe3OjeR?= NGfueogyKM7:TR?= NYf4VGF[PCCq NFTPb|ZFVVOR Mo\ZV5Ri[mmuaYrld{BxPTN? MV6xOFYyOjV|Mh?=
T29 M{fMdGFxd3C2b4Ppd{BCe3OjeR?= NH;oVHo2OCCwTR?= MUO0PEBpKA>? NX20U2RYTE2VTx?= MoDFTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NVTQVGVnOTZ5N{ixO|k>
T29Kt1 NID3Z4hCeG:ydH;zbZMhSXO|YYm= NFrFPJE2OCCwTR?= NGjKeJo1QCCqIB?= M4L5ZmROW09? M1izdmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NGnm[pgyPjd5OEG3PS=>
HCT116 NWfo[nZsSXCxcITvd4l{KEG|c3H5 NVroNodsPTBibl2= MVe0PEBpKA>? MVvEUXNQ MkTJTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MVOxOlc4QDF5OR?=
HKe-3 NWrWcWhGSXCxcITvd4l{KEG|c3H5 NELzUVA2OCCwTR?= NULYdlV6PDhiaDC= M{Xh[GROW09? M{DzXGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NYf6WolROTZ5N{ixO|k>
NB-1691 NHraTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHBcVkyKM7:TR?= Mmm2O|IhcA>? M4r4eWlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?= NHfOUWsyPzZ6OU[4OC=>
CHLA-255 M3;TWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmxJO69VQ>? NEC3eIk4OiCq MkiwTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDJn M2nOTVE4Pjh7Nki0
SK-N-AS MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnC[VRvOSEQvF2= MX23NkBp NVX1NFZSUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=> MVqxO|Y5QTZ6NB?=
NB-1691 M3vZS2Z2dmO2aX;uJGF{e2G7 M{n6RlExKG6P NYi0bYFLOjRiaB?= NV76UHlOW2mpbnnmbYNidnSueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? NXXYdXNmOTd4OEm2PFQ>
CHLA-255 NWDXPZhETnWwY4Tpc44hSXO|YYm= MXGxNEBvVQ>? NXXSVolxOjRiaB?= Mmi2UY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V? MV6xO|Y5QTZ6NB?=
RPMI 8226 NVP3[JlxTnWwY4Tpc44hSXO|YYm= NXfW[IZGOjBibl2= M4DSNVghcA>? MWrTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NWrudYozOTl2M{[wOVA>
MM.1S NUXBcWIzTnWwY4Tpc44hSXO|YYm= MXSyNEBvVQ>? NGnNVYY5KGh? MXLTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> M{H2ZVE6PDN4MEWw
U266 MknySpVv[3Srb36gRZN{[Xl? MUmyNEBvVQ>? M{XaOFghcA>? M1XjZnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 M335UlE6PDN4MEWw
OPM1 NUfSUFF5TnWwY4Tpc44hSXO|YYm= M1nVb|IxKG6P M2TGWFghcA>? Mn\4V4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MXexPVQ{PjB3MB?=
INA6 M1PNXmZ2dmO2aX;uJGF{e2G7 MkPFNlAhdk1? M3zp[VghcA>? NUjJd3lpW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NWTwZ4pGOTl2M{[wOVA>
OPM2 MmPTSpVv[3Srb36gRZN{[Xl? NW\yVFd1OjBibl2= M{jVfFghcA>? NG\6SYhUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MoHKNVk1OzZyNUC=
RPMI 8226 MkTkSpVv[3Srb36gRZN{[Xl? M1zR[VIxKG6P NGHHNm05KGh? M2LifGlv\HWlZYOgSG5CKHO7boTo[ZNqew>? MYmxPVQ{PjB3MB?=
BaF/3 Ml3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[yeJN3OTByIH7N MVS0PEBp M1zsc2lEPTB;Nj6yJI5O M1LUNVIxOzB3Nkmy
BaF/3-p210 M33I[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7NNVAxKG6P NXzOXZlJPDhiaB?= MXXJR|UxRTRwNzDuUS=> NUTjSGhXOjB|MEW2PVI>
TCC-S NH24bGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojjNVAxKG6P NEL3eVE1QCCq MoXLTWM2OD1{Lkigcm0> NG\rcpUzODNyNU[5Ni=>
BaF/3 MlvTSpVv[3Srb36gRZN{[Xl? MkL3OkBvVQ>? MUS0PEBp NIPTPGpKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q> MUKyNFMxPTZ7Mh?=
BaF/3-p210 MkDGSpVv[3Srb36gRZN{[Xl? Mk\OOkBvVQ>? MUi0PEBp NFHLeY1KdmS3Y3XzJIEhe2yrZ3j0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 MmDWNlA{ODV4OUK=
BaF/3-p210 NIT5Z4RHfW6ldHnvckBCe3OjeR?= M{XaclYhdk1? M{XlVlI1KGh? M3nyO3Jm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk NEGySHQzODNyNU[5Ni=>
Raji NFfRfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLNNUDPxE1? NYjRUYN1OjRiaB?= Mo\4VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NGD3d5UzOTF5MEm4PC=>
LCL-1 NX7pRZhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\mNoZoOSEQvF2= MXKyOEBp NWrLVpJqWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MYGyNVE4ODl6OB?=
LCL-2 NVLDOoUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3kNUDPxE1? NGnjR4kzPCCq MoroVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MWeyNVE4ODl6OB?=
BJAB NVfNbndHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXFenkyKM7:TR?= NFvsUngzPCCq Mn7hVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MWKyNVE4ODl6OB?=
SNT-13 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnZPFNGOSEQvF2= NVjCd4pQOjRiaB?= NHGwNWxT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MVWyNVE4ODl6OB?=
SNT-16 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxJO69VQ>? Mmm0NlQhcA>? NX3MT4lYWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NHm0S|kzOTF5MEm4PC=>
Jurkat MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr5SIkyKM7:TR?= M{j0XlI1KGh? MV3S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NUfueFJ4OjFzN{C5PFg>
KAI-3 NXTTNYZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHw[5FpOSEQvF2= NIPlV4YzPCCq NHS1TlhT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MUWyNVE4ODl6OB?=
SNK-6 NWOxfW1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOxJO69VQ>? NVm5U|NJOjRiaB?= NGfXNYJT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NGXJRlEzOTF5MEm4PC=>
KHYG-1 NHezcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3tU2wyKM7:TR?= NEG3[WczPCCq MkPPVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NYK0bXVKOjFzN{C5PFg>
SNT-16 MVPBdI9xfG:|aYOgRZN{[Xl? MkLwNUDPxE1? M4DUOlYhcA>? M332VGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Ml\NNlEyPzB7OEi=
Jurkat MkX1RZBweHSxc3nzJGF{e2G7 NYHMSmtjOSEQvF2= MUi2JIg> M{LYTGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MUSyNVE4ODl6OB?=
KAI-3 NFz4OVFCeG:ydH;zbZMhSXO|YYm= MlvhNUDPxE1? M3nCcFYhcA>? MXfJcoR2[2W|IHPlcIwh[XCxcITvd4l{ M1THVVIyOTdyOUi4
KHYG-1 MW\BdI9xfG:|aYOgRZN{[Xl? M1H0bFEh|ryP NYjFUI5uPiCq MVHJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MYKyNVE4ODl6OB?=
SNT-13 MnLPRY51cX[rcnHsJGF{e2G7 Ml7pNUDPxE1? NHrvU5kzPCCq MVHJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> M3P4d|IyOTdyOUi4
SNT-16 NHXDWmRCdnSrdnnyZYwhSXO|YYm= M{nobVEh|ryP MWSyOEBp M1;2PGlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? M3fJelIyOTdyOUi4
KAI-3 NYnLW5JTSW62aY\pdoFtKEG|c3H5 NXLFPY5QOSEQvF2= MWCyOEBp NWf0d41JUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MmHLNlEyPzB7OEi=
SNK-6 M4T3c2FvfGm4aYLhcEBCe3OjeR?= MV:xJO69VQ>? NUjUbYZXOjRiaB?= NHvTOYFKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? M2LaPVIyOTdyOUi4
RAW 264.7 Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK2NVAxKG6P MlfNOFghcA>? NWO1eJRYWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M2XF[lIzPDJ5MUW0
A375 M17pV2Fxd3C2b4Ppd{BCe3OjeR?= MWSxNEBvVQ>? M1:xelI1KGh? MXHJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NWTQNVJoOjNyN{mwPFM>
BLM M4OwcWFxd3C2b4Ppd{BCe3OjeR?= M4G5eFExKG6P NYXDc20zOjRiaB?= MV\JcoR2[2W|IHPlcIwh[XCxcITvd4l{ MofENlMxPzlyOEO=
A375 MW\BeZRweGijZ4mgRZN{[Xl? NYjx[YRwOTBibl2= NVzTWIVLOTJiaB?= MX\JcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= NUCzT2NXOjNyN{mwPFM>
BLM MV\BeZRweGijZ4mgRZN{[Xl? NFPaNVQyOCCwTR?= NY\mVJhtOTJiaB?= M3rxXGlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz MUmyN|A4QTB6Mx?=
H1299 M3XRbmFxd3C2b4Ppd{BCe3OjeR?= NF\jOHo5OCCwTR?= MYqyOEBp M{\hNWROW09? MorlV4Vve2m2aYrld{BPW0OOQzDj[YxteyC2bzDNV2Mu\GW{aY\l[EBqSzlvaX7keYNm\CCjcH;weI9{cXN? M{TCV|I2OzJ|Nkmz
Hut-78 MmD4SpVv[3Srb36gRZN{[Xl? MXqxNFAhdk1? NWj1TWhyOjRiaB?= NGTzdI9FVVOR MlXuSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w MXyyOVY5OTN|NR?=
H9 NXLP[nk3TnWwY4Tpc44hSXO|YYm= M2L2Z|ExOCCwTR?= NH[2eIwzPCCq M4fVWWROW09? MX3Ec5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEyKGW6cILld5Nqd25? MnrkNlU3QDF|M{W=
HH MkO0SpVv[3Srb36gRZN{[Xl? MWWxNFAhdk1? Ml;TNlQhcA>? MonLSG1UVw>? NV:5WI5w\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u MoK2NlU3QDF|M{W=
Hut-78 NHzVc5pOcWe{YYTpc44hSXO|YYm= MofaNVAxKG6P MYSyOEBp MlvlSG1UVw>? MXrS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn M1vKflI2PjhzM{O1
HH NFfVbGdOcWe{YYTpc44hSXO|YYm= NHnEVWQyODBibl2= MlrpNlQhcA>? Mo\SSG1UVw>? MlqzVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlzJR?= NYDYXHNjOjV4OEGzN|U>
U937 NXXRepFOTnWwY4Tpc44hSXO|YYm= M1vuV|ExOCCwTR?= MUG2JIg> NY\WSWFIUW6mdXPld{BKVC16IHX4dJJme3Orb36gbY4hVFCVLYP0bY12dGG2ZXSgWVk{PyCvYXPyc5Bp[Wencx?= MoO0NlU4QTF2N{e=
human PBMC M4nIZ2Z2dmO2aX;uJGF{e2G7 NHK2[4kyODBibl2= M2DKdVI1KGh? NVTyW5ROUW6mdXPld{BKVC16IILlcIVie2V? MWOyOVc6OTR5Nx?=
ES6 Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\2emlEPTB;MD6wNFIyKG6P MXrTRW5ITVJ?
SK-UT-1 NFzBdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j1T2lEPTB;MD6xOlMhdk1? NFTTU|JUSU6JRWK=
SH-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLKVmFoUUN3ME2wMlE4OyCwTR?= NXyzb5NMW0GQR1XS
TE-9 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2iwOmlEPTB;MD6xPFIhdk1? M3TKV3NCVkeHUh?=
A253 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMkC4JI5O M1fJZXNCVkeHUh?=
no-10 M{\2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMkGgcm0> NIHvXW9USU6JRWK=
MMAC-SF MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG4[ng1UUN3ME2wMlIyPiCwTR?= Mmn1V2FPT0WU
A101D NELKXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMkK1JI5O MV;TRW5ITVJ?
NTERA-S-cl-D1 MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWS4PZY2UUN3ME2wMlI1OyCwTR?= Ml3WV2FPT0WU
8-MG-BA NXuxSnZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\rW2lEPTB;MD6yOUBvVQ>? M2XxenNCVkeHUh?=
KNS-42 Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HMTWlEPTB;MD6yOVghdk1? MXnTRW5ITVJ?
LXF-289 NIfsc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\zOGlEPTB;MD6yOlkhdk1? M2TBTnNCVkeHUh?=
OVCAR-4 NYjZWVBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTENHB2UUN3ME2wMlI5QSCwTR?= Mn;lV2FPT0WU
LOUCY NGf1d5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ToXGlEPTB;MD6yPVMhdk1? MUXTRW5ITVJ?
BB65-RCC NXjDPW5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILp[5RKSzVyPUCuN|A1KG6P NUTke3pCW0GQR1XS
D-542MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTsTWM2OD1yLkOyPUBvVQ>? MmTMV2FPT0WU
ONS-76 MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3MRmRKSzVyPUCuN|Mhdk1? NVT6RYcxW0GQR1XS
BB30-HNC NUDiO2RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XSc2lEPTB;MD6zN|Uhdk1? MWTTRW5ITVJ?
KS-1 M4HFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq0SGpIUUN3ME2wMlM1KG6P NV34fGoxW0GQR1XS
A388 M3j2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLKTWM2OD1yLkO1OkBvVQ>? NH;0NnlUSU6JRWK=
ES8 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DMUmlEPTB;MD60JI5O NEHXNG5USU6JRWK=
MZ2-MEL NWryT5lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;pUnRDUUN3ME2wMlQxPyCwTR?= NF3EUYpUSU6JRWK=
HCC2998 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILtbYxKSzVyPUCuOFEzKG6P M3\Ve3NCVkeHUh?=
D-247MG NV7rR2FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrV[o1KSzVyPUCuOFE{KG6P NFPLU2VUSU6JRWK=
ACN MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPoTWM2OD1yLkSxO{BvVQ>? NHXMS4pUSU6JRWK=
LB2518-MEL M4TWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwNEK1JI5O MWHTRW5ITVJ?
ES1 Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u3[GlEPTB;MD60N{BvVQ>? MoXBV2FPT0WU
HCE-T Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETHU3RKSzVyPUCuOFM6KG6P M1\UWHNCVkeHUh?=
OS-RC-2 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7tOZZmUUN3ME2wMlQ1KG6P NXPOT5lTW0GQR1XS
MFH-ino NYPNZmVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\jVY5nUUN3ME2wMlQ1OyCwTR?= MWXTRW5ITVJ?
OCUB-M MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfuO49KSzVyPUCuOFQ4KG6P NFjXOGVUSU6JRWK=
CP66-MEL MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrtfFlXUUN3ME2wMlQ4OyCwTR?= M1eyPHNCVkeHUh?=
LB771-HNC M33EeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\ZOJhKSzVyPUCuOFc1KG6P NHnBOGlUSU6JRWK=
DSH1 NYfTSXBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwNEigcm0> MXrTRW5ITVJ?
HUTU-80 M3yxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX3fVdKSzVyPUCuOVM{KG6P NU[zR4VGW0GQR1XS
CESS MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHBVFZFUUN3ME2wMlU{QCCwTR?= MmHxV2FPT0WU
NCI-H747 MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwNUO5JI5O NEPJXndUSU6JRWK=
HT-144 MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnMTYdiUUN3ME2wMlU4PiCwTR?= NVTnOJNVW0GQR1XS
COLO-829 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwNkG0JI5O MYfTRW5ITVJ?
A4-Fuk MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXsSJBJUUN3ME2wMlYzOyCwTR?= NEC2W|RUSU6JRWK=
GI-ME-N NHXoSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwNkO0JI5O NWXzWm9oW0GQR1XS
LB831-BLC M{P4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorDTWM2OD1yLk[0NUBvVQ>? NUPa[XFtW0GQR1XS
HOP-62 NFn2emdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwNkS3JI5O NHj0R4xUSU6JRWK=
BB49-HNC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nhUWlEPTB;MD62OVIhdk1? NVmxVpJUW0GQR1XS
D-336MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TwdWlEPTB;MD62OVchdk1? MX;TRW5ITVJ?
TK10 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnniTWM2OD1yLk[3PUBvVQ>? NH63WVNUSU6JRWK=
Ramos-2G6-4C10 NI\pdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17yWWlEPTB;MD62PVMhdk1? MXrTRW5ITVJ?
LB373-MEL-D M{fhOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwNzDuUS=> MkLRV2FPT0WU
SF126 NWfjTotLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\5V4UyUUN3ME2wMlcxOSCwTR?= NUPlS4ppW0GQR1XS
UACC-257 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXFO5dKSzVyPUCuO|Ehdk1? NYHneopGW0GQR1XS
KINGS-1 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn1TWM2OD1yLkeyNkBvVQ>? MUDTRW5ITVJ?
LS-513 M{TXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT4TWM2OD1yLkezPUBvVQ>? MnyxV2FPT0WU
GI-1 NEToPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDlTWM2OD1yLke2OEBvVQ>? NXXGfW5TW0GQR1XS
ES7 NGfpPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwN{[2JI5O M4fwSXNCVkeHUh?=
LB2241-RCC NELRRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDPfGpKSzVyPUCuPFA1KG6P NVXBVZJIW0GQR1XS
D-263MG NWjVS3l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvBe4VjUUN3ME2wMlgxPyCwTR?= MUHTRW5ITVJ?
SW684 NUfueZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXLV5dKSzVyPUCuPFIyKG6P NEW1c3VUSU6JRWK=
ML-2 MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M12xS2lEPTB;MD64NlEhdk1? NWPqU4lvW0GQR1XS
SK-LMS-1 NFq5dm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwOEW0JI5O M3rnW3NCVkeHUh?=
TE-5 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvZW2lKSzVyPUCuPFY2KG6P MnezV2FPT0WU
QIMR-WIL NYfydYRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwOEi5JI5O M4C5bHNCVkeHUh?=
NCI-H1355 NFy0UFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLncmlKSzVyPUCuPFk2KG6P MlTRV2FPT0WU
SNB75 NVXXPIZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrsTWM2OD1yLkmxNkBvVQ>? MVfTRW5ITVJ?
RXF393 NU\ScIl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HJWWlEPTB;MD65NVQhdk1? NHL6[XFUSU6JRWK=
IST-MEL1 M33YUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13IfGlEPTB;MD65NVchdk1? MnywV2FPT0WU
SF268 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrqOZRKSzVyPUCuPVI{KG6P Mn7IV2FPT0WU
KALS-1 NHvidHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;WN3ZXUUN3ME2wMlkzPSCwTR?= MULTRW5ITVJ?
HC-1 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwOUe1JI5O M4qzTHNCVkeHUh?=
SW872 NIrifFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:1TWM2OD1yLkm5OkBvVQ>? MVnTRW5ITVJ?
PSN1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnhSmdVUUN3ME2xMlAyKG6P MnPXV2FPT0WU
TE-1 M1\iUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHVUlJPUUN3ME2xMlA{KG6P NILCWllUSU6JRWK=
TE-10 NGLUUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3XTWM2OD1zLkCzJI5O MlTUV2FPT0WU
RKO M3G1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrLc|Z7UUN3ME2xMlA3KG6P M{m1fHNCVkeHUh?=
LC-2-ad NVnlZW1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwMEigcm0> NGq1VoJUSU6JRWK=
SK-MM-2 MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q5RWlEPTB;MT6wPUBvVQ>? Mkf4V2FPT0WU
VA-ES-BJ M4K4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmflTWM2OD1zLkC5JI5O M1XFfnNCVkeHUh?=
MZ7-mel M2frN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFwMEmgcm0> Mo\jV2FPT0WU
D-392MG NHvZcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;VdIlKSzVyPUGuNUBvVQ>? M1L5bXNCVkeHUh?=
CCRF-CEM MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFwMUOgcm0> M3fvSnNCVkeHUh?=
EM-2 M2PIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzsTWM2OD1zLkG2JI5O M{DTR3NCVkeHUh?=
HAL-01 M4\tSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwMUigcm0> NEH2TJVUSU6JRWK=
TE-8 NWG5b4dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnydXJKSzVyPUGuNVkhdk1? MYnTRW5ITVJ?
NCI-H1882 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYWzcmxmUUN3ME2xMlIhdk1? M2L5PHNCVkeHUh?=
Daudi MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Wx[WlEPTB;MT6yNkBvVQ>? M2DKZXNCVkeHUh?=
BL-41 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfmWXRKSzVyPUGuNlUhdk1? Mn7SV2FPT0WU
SR Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS0TWM2OD1zLkK1JI5O Ml7XV2FPT0WU
KM12 M1nST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGSxW4lKSzVyPUGuNlchdk1? NVS4O286W0GQR1XS
K5 NITTVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojFTWM2OD1zLkK4JI5O NXnZNW93W0GQR1XS
A3-KAW Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVizWW9pUUN3ME2xMlI5KG6P NVvOOmhnW0GQR1XS
CMK MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe2c2Y1UUN3ME2xMlI6KG6P Mmi1V2FPT0WU
Calu-6 M1SzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwMkmgcm0> NUjBRnNGW0GQR1XS
IST-SL2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG0VGZHUUN3ME2xMlMyKG6P NWToPVVxW0GQR1XS
OPM-2 NWfIUFZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjjXYNUUUN3ME2xMlM{KG6P Moi5V2FPT0WU
DU-4475 NEC5VVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT5TWM2OD1zLkO2JI5O M1\YeXNCVkeHUh?=
ECC12 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTFwM{egcm0> NE\KbYRUSU6JRWK=
L-540 M1vw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfTNmhZUUN3ME2xMlM4KG6P MonxV2FPT0WU
CAS-1 NE\PZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrFVWFPUUN3ME2xMlM4KG6P MYnTRW5ITVJ?
PF-382 Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\TTWM2OD1zLkS3JI5O Ml3MV2FPT0WU
LS-411N NVG2XIZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nwbWlEPTB;MT61N{BvVQ>? NEnLUHpUSU6JRWK=
NCI-H69 M3LuN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;aTWM2OD1zLkW0JI5O NG\pXlVUSU6JRWK=
NB12 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13ZcGlEPTB;MT61OkBvVQ>? MXPTRW5ITVJ?
HEL Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfTVWRuUUN3ME2xMlYyKG6P NFXrZmNUSU6JRWK=
GCIY MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HZbWlEPTB;MT62NkBvVQ>? MVvTRW5ITVJ?
EHEB Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rESWlEPTB;MT62O{BvVQ>? M3\ldHNCVkeHUh?=
TGBC1TKB NF72OIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLWNVRsUUN3ME2xMlcyKG6P NInSd3hUSU6JRWK=
KURAMOCHI MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO2TndKSzVyPUGuO|Ihdk1? NEf3OVFUSU6JRWK=
U-266 NHHCeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwN{[gcm0> M4\FeHNCVkeHUh?=
LC4-1 NVjxfpU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS4TWM2OD1zLke5JI5O NXPWcHBnW0GQR1XS
NCI-H2126 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLQTWM2OD1zLkigcm0> NFXZN|NUSU6JRWK=
NCI-H1092 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jjVmlEPTB;MT64JI5O Mn[0V2FPT0WU
GB-1 M3y2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILD[YRKSzVyPUGuPFEhdk1? NI\5TWVUSU6JRWK=
MV-4-11 M3nhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\T[ZRqUUN3ME2xMlgzKG6P M1fZOnNCVkeHUh?=
Becker M4LkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFwOEOgcm0> NFizN5JUSU6JRWK=
MPP-89 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwOEmgcm0> NH7pNHpUSU6JRWK=
BE-13 MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT5Z|lKSzVyPUGuPVMhdk1? MoTyV2FPT0WU
697 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3jdXJKSzVyPUGuPVkhdk1? MlzuV2FPT0WU
NKM-1 M1jH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonRTWM2OD1{IH7N MoXaV2FPT0WU
NB13 MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fFUGlEPTB;MjDuUS=> NXv0O2dYW0GQR1XS
LS-123 NHrwRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7YTWM2OD1{LkCyJI5O M2qyOXNCVkeHUh?=
NB17 NUW0eXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjyTWM2OD1{LkC0JI5O M3zSZXNCVkeHUh?=
LAN-6 Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjETWM2OD1{LkC1JI5O NYTRSVhJW0GQR1XS
EW-24 NFPO[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljwTWM2OD1{LkC4JI5O M{DzRXNCVkeHUh?=
NOS-1 MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKxO|dHUUN3ME2yMlEyKG6P M3LM[3NCVkeHUh?=
BL-70 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJwMUKgcm0> NFPXS4NUSU6JRWK=
GT3TKB MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{SzV2lEPTB;Mj6xNkBvVQ>? MoLPV2FPT0WU
HH MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqzTWM2OD1{LkGzJI5O NXm2cWV2W0GQR1XS
KE-37 NUXWdWxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHGV3RKSzVyPUKuNVMhdk1? MkHsV2FPT0WU
MOLT-4 M2\lVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYOzRpdpUUN3ME2yMlE{KG6P NU\k[4tUW0GQR1XS
EKVX M3fVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LXe2lEPTB;Mj6xOEBvVQ>? MmO4V2FPT0WU
KGN NHL3[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPWcGE1UUN3ME2yMlE2KG6P MVHTRW5ITVJ?
ES4 M3jOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDx[VhNUUN3ME2yMlE3KG6P M4i0VHNCVkeHUh?=
SJSA-1 NUnpN|F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\uUmZpUUN3ME2yMlIyKG6P MnTqV2FPT0WU
KMOE-2 NIn6RZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnFeZRqUUN3ME2yMlI{KG6P MmXUV2FPT0WU
NB5 M{TQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu0TWM2OD1{LkK3JI5O NYP5U3J{W0GQR1XS
BC-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnGfYxKSzVyPUKuN|Ehdk1? M1PkcXNCVkeHUh?=
NB10 M2H6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17L[2lEPTB;Mj6zNkBvVQ>? M1rZ[3NCVkeHUh?=
RPMI-8226 M3vCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJwM{Wgcm0> MkfnV2FPT0WU
SCC-3 NUPYc2dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr5VZhKSzVyPUKuN|chdk1? NV7j[ZBrW0GQR1XS
ARH-77 MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;Jc4VKSzVyPUKuN|ghdk1? M2naUXNCVkeHUh?=
NCI-H748 M1Oyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnLWWtKSzVyPUKuN|khdk1? MWPTRW5ITVJ?
KU812 M4HReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYraOG8xUUN3ME2yMlQzKG6P NH3Mb4tUSU6JRWK=
NCI-H64 M2L4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJwNESgcm0> M3vOS3NCVkeHUh?=
NB69 NVnUfI1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETrfldKSzVyPUKuOFYhdk1? MUjTRW5ITVJ?
KNS-81-FD MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O0RWlEPTB;Mj60PEBvVQ>? MYPTRW5ITVJ?
LB1047-RCC MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJwNUegcm0> M2jifXNCVkeHUh?=
EB-3 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT1NXNZUUN3ME2yMlY3KG6P M4XIbnNCVkeHUh?=
Mo-T NWrJSlNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXrfIVQUUN3ME2yMlc1KG6P NXnRe3ZoW0GQR1XS
EW-16 NXu1fo9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJwN{Wgcm0> M33tZ3NCVkeHUh?=
CTV-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW3[IZoUUN3ME2yMlghdk1? MkDDV2FPT0WU
ETK-1 NWPLNVFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi2OWpIUUN3ME2yMlg1KG6P M2j1bHNCVkeHUh?=
C2BBe1 M3juSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHXPG9xUUN3ME2yMlg6KG6P NF;FWJhUSU6JRWK=
MOLT-16 Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLlTWM2OD1{Lki5JI5O M2[2UnNCVkeHUh?=
SW954 NGrodHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJwOTDuUS=> M1riRXNCVkeHUh?=
HT M2POcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPwTWM2OD1|LkCyJI5O M1XwdnNCVkeHUh?=
KARPAS-299 NHfXN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zSVWlEPTB;Mz6wOkBvVQ>? MmDzV2FPT0WU
MONO-MAC-6 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\2TWM2OD1|LkGgcm0> MVLTRW5ITVJ?
CGTH-W-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnROnZDUUN3ME2zMlEhdk1? MmjTV2FPT0WU
SK-PN-DW NEfWVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTNwMUSgcm0> NYnud3h7W0GQR1XS
CW-2 NXvZbXdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTNwMkGgcm0> MlvBV2FPT0WU
SK-N-DZ MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULOWW5YUUN3ME2zMlI3KG6P MoXvV2FPT0WU
NEC8 M1OzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzLRoFNUUN3ME2zMlM2KG6P M3LaNnNCVkeHUh?=
LB996-RCC M1jFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojSTWM2OD1|LkSgcm0> MnrZV2FPT0WU
DB MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTNwNEGgcm0> Mk[yV2FPT0WU
TE-15 MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlToTWM2OD1|LkSzJI5O MX3TRW5ITVJ?
COR-L88 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXpWmUzUUN3ME2zMlQ4KG6P MnuxV2FPT0WU
LAMA-84 NFrEWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTNwNEmgcm0> M{nIVXNCVkeHUh?=
MEG-01 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXUepFKSzVyPUOuOFkhdk1? NU\6dZJMW0GQR1XS
LOXIMVI NGezUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqxfVNKSzVyPUOuOUBvVQ>? M1\XS3NCVkeHUh?=
RPMI-8402 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTNwNTDuUS=> NISweJdUSU6JRWK=
KARPAS-45 M2S4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TZemlEPTB;Mz61OEBvVQ>? M{\vTHNCVkeHUh?=
HCC1187 M{CyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;0UHRmUUN3ME2zMlU1KG6P NULwfFdSW0GQR1XS
MZ1-PC NFH2eFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTNwNUSgcm0> NHLoZphUSU6JRWK=
no-11 NHzabZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWThOW5lUUN3ME2zMlU2KG6P MnnyV2FPT0WU
EVSA-T NGDNN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTNwNjDuUS=> NXTYUlZSW0GQR1XS
DJM-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTNwNkOgcm0> NF\VfYRUSU6JRWK=
COLO-684 NXHydpJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XOUGlEPTB;Mz62OkBvVQ>? MnHtV2FPT0WU
NMC-G1 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNwNkigcm0> M{nxO3NCVkeHUh?=
LC-1F MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPDRmVqUUN3ME2zMlc1KG6P NEnIb2pUSU6JRWK=
RL95-2 NHzrV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LrW2lEPTB;Mz63PUBvVQ>? MnToV2FPT0WU
COLO-320-HSR NGj6OXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHCeXh3UUN3ME2zMlkzKG6P MXLTRW5ITVJ?
RCC10RGB NY\UNZFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33Jb2lEPTB;Mz65N{BvVQ>? MoTLV2FPT0WU
HD-MY-Z M2\aW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTNwOUOgcm0> M1Sxe3NCVkeHUh?=
NCI-H2141 M2rGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K3V2lEPTB;ND6wOUBvVQ>? M3TJeXNCVkeHUh?=
K-562 NEXqe5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S3eWlEPTB;ND6xNkBvVQ>? Mn;iV2FPT0WU
NCI-H1648 NEHZdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz4TWM2OD12LkGzJI5O NEXRSVdUSU6JRWK=
OMC-1 NVv3fJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHjTWM2OD12LkG4JI5O NWS3e3JtW0GQR1XS
LB647-SCLC NYj4bFlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfHeJFKSzVyPUSuNlIhdk1? MkfnV2FPT0WU
TE-12 M{XGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRwMkWgcm0> NHG1S4hUSU6JRWK=
NOMO-1 MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojCTWM2OD12LkOzJI5O NUHvW4U3W0GQR1XS
Raji NVG2Tm5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRwNE[gcm0> MlLFV2FPT0WU
NALM-6 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr6TWM2OD12LkS5JI5O M3fNbnNCVkeHUh?=
HL-60 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHCTWM2OD12Lk[3JI5O M1vIRnNCVkeHUh?=
IST-SL1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXxTWM2OD12Lk[4JI5O NWfQOWF4W0GQR1XS
MHH-PREB-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi4ZYFKSzVyPUSuPFYhdk1? MmPZV2FPT0WU
MHH-NB-11 NH3S[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTRwOUGgcm0> NUTRPINbW0GQR1XS
JiyoyeP-2003 NYXK[446T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTVibl2= MojoV2FPT0WU
SBC-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7MTWM2OD13LkCxJI5O M{jHfXNCVkeHUh?=
CHP-126 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPtU2NnUUN3ME21MlA3KG6P NVjPUZVZW0GQR1XS
LU-139 NID6RZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP5VG9IUUN3ME21MlE{KG6P NH3iTXFUSU6JRWK=
NCI-SNU-5 NFLKVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTVwMUegcm0> M4fhcXNCVkeHUh?=
SW962 NGLQdGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\YTGlEPTB;NT6yNUBvVQ>? NIO4UnFUSU6JRWK=
EW-1 NW\oV2tyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ftOmlEPTB;NT6zNUBvVQ>? M{fnc3NCVkeHUh?=
NCI-H1417 NUG1RXlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\tcWhzUUN3ME21MlUyKG6P NX\iXopNW0GQR1XS
LU-65 NH31Xo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTVwOESgcm0> NYrQVFFxW0GQR1XS
D-502MG NYfZVItzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTZwM{egcm0> NY[3W2J7W0GQR1XS
BC-3 Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6wTWM2OD14Lk[xJI5O NWDBeYhtW0GQR1XS
GDM-1 NXvZVGdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HvT2lEPTB;Nj63O{BvVQ>? MnHNV2FPT0WU
NCI-H2196 MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTZwODDuUS=> NF3VUJlUSU6JRWK=
NB1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnQTWM2OD14Lki4JI5O MXHTRW5ITVJ?
NCI-H345 M3fkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\YTWM2OD15LkKgcm0> Mn33V2FPT0WU
SU-DHL-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTdwMkSgcm0> Mk\yV2FPT0WU
JVM-2 M3rPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPuR5VKSzVyPUeuNlghdk1? MV7TRW5ITVJ?
LU-134-A MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDTN21KSzVyPUeuN|khdk1? M3\YN3NCVkeHUh?=
NCI-H1694 M1HNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTBTWM2OD15LkW4JI5O NW[4[G9qW0GQR1XS
NCI-SNU-16 NITtN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTdwNkWgcm0> NF3ySWRUSU6JRWK=
L-363 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjwdYlqUUN3ME23Mlchdk1? M3T5NnNCVkeHUh?=
KG-1 M1[x[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEmwbVhKSzVyPUeuPVQhdk1? Ml\WV2FPT0WU
MN-60 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[3UmVKSzVyPUiuNVQhdk1? NXzCVY9XW0GQR1XS
NB6 MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm0cmFKSzVyPUiuOFghdk1? M1rDZXNCVkeHUh?=
MLMA MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv3bFBKSzVyPUiuPFUhdk1? M3;JbXNCVkeHUh?=
ATN-1 NEHQWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:3PJZHUUN3ME24Mlg6KG6P M{HSc3NCVkeHUh?=
SK-NEP-1 NFzyZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHTZXpsUUN3ME25MlAyKG6P NYT2NoZZW0GQR1XS
DMS-114 MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYewfFZQUUN3ME25MlYzKG6P MlHiV2FPT0WU
CTB-1 M4jIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDReFJKSzVyPUmuOlchdk1? MWPTRW5ITVJ?
NCI-H2081 NX[zcHlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;VV25KSzVyPUGwMlA6KG6P MlmzV2FPT0WU
ES5 M4HuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XqN2lEPTB;MUCuN|ghdk1? MnXPV2FPT0WU
HCC1599 NUXqNoI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW4TWM2OD1zMT65NUBvVQ>? NIHQXWNUSU6JRWK=
NCI-H23 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PEPGlEPTB;MUKuNVIhdk1? MojwV2FPT0WU
NCI-H1581 NHfWVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi0b3o5UUN3ME2xNk4zQCCwTR?= NYfqPI1uW0GQR1XS
JVM-3 NUjPXXNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\LVoNNUUN3ME2xNk46QSCwTR?= M{fDUXNCVkeHUh?=
NCI-SNU-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH6TWM2OD1zMz6xPUBvVQ>? MknwV2FPT0WU
NB7 M2rmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjOdZlKSzVyPUG1MlkzKG6P M161OnNCVkeHUh?=
JAR MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF4LkGzJI5O M2nR[3NCVkeHUh?=
TGW NXHt[pQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDhTWM2OD1zNj60PEBvVQ>? NHTmT4FUSU6JRWK=
U-87-MG NXXBVZZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF4Lke2JI5O M1fvXXNCVkeHUh?=
NCI-H1436 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml65TWM2OD1zNz6wNUBvVQ>? MoPCV2FPT0WU
GOTO M{[yWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF5LkC2JI5O MUfTRW5ITVJ?
COLO-800 MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF5Lk[0JI5O MnPhV2FPT0WU
MFM-223 NUXXN|U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGzTWM2OD1zNz65NUBvVQ>? NX\EdJpzW0GQR1XS
EW-18 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF5Lkm2JI5O NGf0d5JUSU6JRWK=
NB14 NWrtdlhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF5Lkm4JI5O MkTQV2FPT0WU
EB2 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn62TWM2OD1zOD6wPEBvVQ>? MX;TRW5ITVJ?
EoL-1- MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrB[m5KSzVyPUG4MlMyKG6P NUjk[5lpW0GQR1XS
NCCIT NHTFW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2xRoRKSzVyPUG4MlM3KG6P NGqxfZFUSU6JRWK=
DG-75 M2O4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XOWGlEPTB;MUiuOlEhdk1? MmfGV2FPT0WU
HCC2218 NXjHUoI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;aUWlEPTB;MUmuOUBvVQ>? M3fyd3NCVkeHUh?=
TE-6 NXS0cY5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzhdoFKSzVyPUKwMlA5KG6P MkfUV2FPT0WU
SF539 M3L5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXZS5dMUUN3ME2yNE43PyCwTR?= MX;TRW5ITVJ?
NCI-H446 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fBOmlEPTB;MkGuNVghdk1? Ml;uV2FPT0WU
IST-MES1 Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrjdoFKSzVyPUKyMlc4KG6P NI\INolUSU6JRWK=
NCI-H82 M1vOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnhc5pKSzVyPUKzMlAzKG6P NVWy[3I4W0GQR1XS
HCC2157 M1nwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJ|LkGzJI5O NWjJcJA1W0GQR1XS
EW-12 Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DabWlEPTB;MkOuNVchdk1? NHO1O45USU6JRWK=
SIMA MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\yTGlEPTB;MkOuN|ghdk1? MlnCV2FPT0WU
DOHH-2 MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO4XHFTUUN3ME2yN{41PSCwTR?= NXrDR2pOW0GQR1XS
IM-9 MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFroWWlKSzVyPUKzMlU1KG6P M2nr[HNCVkeHUh?=
EC-GI-10 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrVeIFKSzVyPUK0MlI{KG6P M1m4SHNCVkeHUh?=
HDLM-2 M3:zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ2LkW0JI5O MorkV2FPT0WU
LS-1034 NHnobJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJ3Lke1JI5O MlPRV2FPT0WU
REH NH3oO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDRU5RbUUN3ME2yOk41OSCwTR?= NFTnbmlUSU6JRWK=
LU-165 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ4LkeyJI5O MkXoV2FPT0WU
NH-12 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TGU2lEPTB;MkeuOlchdk1? NV[1SXdFW0GQR1XS
WSU-NHL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLOTWM2OD1{OD6zPUBvVQ>? MVXTRW5ITVJ?
ECC4 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJ6Lke5JI5O NWPGZmZpW0GQR1XS
OCI-AML2 NHrZT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLOTWM2OD1{OT62PUBvVQ>? MX7TRW5ITVJ?
EW-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfzTWM2OD1|MD61PUBvVQ>? NFq3cYJUSU6JRWK=
NCI-H526 MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzqNm5KSzVyPUOyMlU1KG6P MWLTRW5ITVJ?
NCI-H719 M{HLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[2NmlEPTB;M{SuN|Ehdk1? MlXCV2FPT0WU
KARPAS-422 M1PIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS5TWM2OD1|NT6wOEBvVQ>? NFfPNZdUSU6JRWK=
SK-MEL-1 Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7ITWM2OD1|NT6xO{BvVQ>? MXjTRW5ITVJ?
ES3 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXBPWtKSzVyPUO1MlE6KG6P NFrrO21USU6JRWK=
UACC-812 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ruNmlEPTB;M{WuOFQhdk1? NEjwfFhUSU6JRWK=
C8166 NIfEW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTuboFRUUN3ME2zOU44KG6P MmnmV2FPT0WU
MDA-MB-134-VI M{nkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTDTWM2OD1|NT64O{BvVQ>? M3\Fb3NCVkeHUh?=
D-283MED NXXFTW5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXy4PYZwUUN3ME2zO{44QSCwTR?= NVvx[3ZxW0GQR1XS
SHP-77 M3i1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjYTWM2OD1|OD6wN{BvVQ>? NIq0c|lUSU6JRWK=
NCI-H2227 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPPTWM2OD12MD60PUBvVQ>? M{TFV3NCVkeHUh?=
SKM-1 Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jzTWlEPTB;NEKuOlMhdk1? NXvFV2d4W0GQR1XS
L-428 NILjSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3LWFZKSzVyPUSzMlg3KG6P M4DhdXNCVkeHUh?=
RPMI-6666 NGXIWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHReos5UUN3ME20OU45QSCwTR?= NI\yPVNUSU6JRWK=
NCI-H716 NFKwZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnmwTWM2OD12OD64NUBvVQ>? MXzTRW5ITVJ?
DMS-79 M4nGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjjWHNGUUN3ME21NE44OSCwTR?= M2nGbnNCVkeHUh?=
RS4-11 M2XSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHxbII1UUN3ME21NE45QCCwTR?= NE\lR4xUSU6JRWK=
NCI-H720 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:yS|RKSzVyPUWxMlEyKG6P M2DQcXNCVkeHUh?=
MC-CAR NVG0OW1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TuXmlEPTB;NUGuOVIhdk1? M13me3NCVkeHUh?=
TALL-1 Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPtS|ZwUUN3ME21N{46OSCwTR?= MYHTRW5ITVJ?
NCI-N87 NXflU|hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHU[5lKSzVyPUW0MlE5KG6P MkjaV2FPT0WU
P30-OHK NHqxUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTV2Lk[xJI5O NIDlW4tUSU6JRWK=
LP-1 NFnWUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32yNGlEPTB;NkGuNlghdk1? NUW0UFdiW0GQR1XS
YT NXvwbG8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmroTWM2OD14MT64JI5O NX\ndXI{W0GQR1XS
MRK-nu-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHLeYlKSzVyPU[xMlgzKG6P MnnGV2FPT0WU
BT-474 NXrEblFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXBUmZKSzVyPU[1JI5O Mk[0V2FPT0WU
NCI-H322M M1\E[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfCTWM2OD14Nj6xNUBvVQ>? MVfTRW5ITVJ?
NCI-H128 M3TYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfEb3BUUUN3ME23OE44PyCwTR?= NUn3b|U3W0GQR1XS
KMS-12-PE MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jCeGlEPTB;N{[uNlQhdk1? NU\IWWJuW0GQR1XS
KP-N-YS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqzTlZJUUN3ME23Ok44PCCwTR?= MkXyV2FPT0WU
ALL-PO MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\5WGRHUUN3ME23O{43PiCwTR?= MVrTRW5ITVJ?
EW-13 NEDzVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTXfFduUUN3ME23O{44PiCwTR?= MmS0V2FPT0WU
EW-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTd6LkWyJI5O M13PbnNCVkeHUh?=
SK-N-FI NVTY[4luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWThWWVCUUN3ME24NE4zKG6P M2Xub3NCVkeHUh?=
CAL-148 NUHHPY1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPIZ3pIUUN3ME24NU45PCCwTR?= NUGxb4lPW0GQR1XS
RL NWXU[4lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTh4LkC5JI5O MWTTRW5ITVJ?
AM-38 MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTh6LkC4JI5O Mn\yV2FPT0WU
RH-1 M{HxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjJTWM2OD17OT64OUBvVQ>? M1rPW3NCVkeHUh?=
NCI-H1770 NETlS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml63TWM2OD1zMEKuOFkhdk1? MU\TRW5ITVJ?
SIG-M5 NIK5[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTFyNT6wOkBvVQ>? NInRZmhUSU6JRWK=
GR-ST NHr2OVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3XOGFKSzVyPUGxN{4{PCCwTR?= MkXMV2FPT0WU
ST486 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3lfGVKSzVyPUGxOE4xPiCwTR?= NYLac|F[W0GQR1XS
NCI-H1650 NUj1fFh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorWTWM2OD1zMUWuNlkhdk1? MU\TRW5ITVJ?
MHH-CALL-2 Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLoT3p4UUN3ME2xNVUvPyCwTR?= MWPTRW5ITVJ?
BV-173 M{jkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PINWlEPTB;MUKyMlcyKG6P M3fE[3NCVkeHUh?=
MC116 NW\S[3M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qxVGlEPTB;MUS4Mlg2KG6P M2Th[3NCVkeHUh?=
NCI-H524 NI\BS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF73RmFKSzVyPUG1PU4yKG6P NEHERnNUSU6JRWK=
SCLC-21H NUTYWmRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vsb2lEPTB;MUW5MlQyKG6P M33Bd3NCVkeHUh?=
NCI-H1304 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF4OT6yNUBvVQ>? NYDNU2FJW0GQR1XS
NCI-H510A MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX24RVBEUUN3ME2xPFUvOzdibl2= NHTSVnpUSU6JRWK=
NCI-H209 M3XKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvKeW1tUUN3ME2xPVYvPTJibl2= MUjTRW5ITVJ?
KM-H2 NETS[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUD1OpV[UUN3ME2xPVcvODVibl2= MoSwV2FPT0WU
NCI-H1395 NFfKeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXUTWM2OD1{MUCuNVMhdk1? NFjTUXhUSU6JRWK=
NCI-H1155 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK2VFdKSzVyPUKzNE4{OiCwTR?= M17Rb3NCVkeHUh?=
COR-L279 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvhTWM2OD1{NUKuNVchdk1? NVjESGF[W0GQR1XS
NCI-H1299 MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnyVmhKSzVyPUK2NU44OSCwTR?= MYrTRW5ITVJ?
EW-22 NHHHVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrPWVdKSzVyPUK2N{44PSCwTR?= NIm1S3RUSU6JRWK=
SK-MEL-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPPflYxUUN3ME2yPFEvQSCwTR?= MYjTRW5ITVJ?
KASUMI-1 MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[3U5p5UUN3ME2yPFMvODVibl2= NHrWcVFUSU6JRWK=
NCI-H187 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rUU2lEPTB;Mki3MlA5KG6P NFHwfYhUSU6JRWK=
NCI-H2171 M1KxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJ6OD65NkBvVQ>? Mn3oV2FPT0WU
LNCaP-Clone-FGC Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIqxZnVKSzVyPUK5OU4zPiCwTR?= NWf2eYN4W0GQR1XS
NCI-H1522 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPhW2NKSzVyPUOwO{4xPSCwTR?= MWnTRW5ITVJ?
SCH NYTONmZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDOTWM2OD1|MkKuNlIhdk1? NGLMTYZUSU6JRWK=
THP-1 NH6xUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH70cGtKSzVyPUOyNk43KG6P NFLZdY1USU6JRWK=
SNU-C1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;wTWM2OD1|NkKuNFkhdk1? NYW2UnhJW0GQR1XS
CA46 NWn0W3dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3IV2JKSzVyPUO3N{43OyCwTR?= MYTTRW5ITVJ?
NCI-H1963 Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjuNlRKSzVyPUO4Ok4yQSCwTR?= M{nKV3NCVkeHUh?=
DEL M1OxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7yfGJKSzVyPUO5NU4zPyCwTR?= MUDTRW5ITVJ?
TUR MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTN7Nj62NUBvVQ>? NV\O[JBuW0GQR1XS
NCI-H226 NVvjbZpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\Feo1KSzVyPUSwN{4zOyCwTR?= NXj5cHNtW0GQR1XS
COLO-668 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7kTWM2OD12MEOuOVchdk1? MkT6V2FPT0WU
CPC-N MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\0R3ZNUUN3ME20NFMvPzdibl2= NYjNcGRVW0GQR1XS
NCI-H889 NXHsNndKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKzcZFzUUN3ME20OlEvQTJibl2= MmXiV2FPT0WU
J-RT3-T3-5 NHXxc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTV|Mj61O{BvVQ>? MojWV2FPT0WU
MSTO-211H NEnYRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLTTWM2OD13N{SuNlYhdk1? NEiwU5RUSU6JRWK=
SCC-15 NE\H[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfxPG57UUN3ME22OlcvPDdibl2= MWfTRW5ITVJ?
SUP-T1 NILDS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;INI46UUN3ME22PFYvODRibl2= NWD3VYhHW0GQR1XS
DMS-153 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTd2Nj64N{BvVQ>? NUnmeFNrW0GQR1XS
MS-1 M3TzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLHT3hKSzVyPUe1PU41OiCwTR?= MnrsV2FPT0WU
TC-YIK MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrHcFFxUUN3ME23PFEvODFibl2= Mm\GV2FPT0WU
RPMI-8866 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\BXIxUUUN3ME2xNFA3NjJ6IN88US=> MVHTRW5ITVJ?
KY821 M1HHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFyM{[uNFQh|ryP MYHTRW5ITVJ?
P31-FUJ MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFzMUKuO|Uh|ryP NUG0SVBjW0GQR1XS
COLO-824 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCxbYhEUUN3ME2xNlYyNjd6IN88US=> MmHHV2FPT0WU
U-698-M NVGxVWp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3VOHpnUUN3ME2yNlYzNjF3IN88US=> M4TEUXNCVkeHUh?=
TE-441-T NHrpXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX2R41KSzVyPUK1NlEvPyEQvF2= NIrmc4RUSU6JRWK=
IMR-5 NGG2SHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\xfGlEPTB;M{SwPU43OiEQvF2= M{DhfHNCVkeHUh?=
NCI-H1838 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D4WGlEPTB;NEG4Ok4{OiEQvF2= M{jCS3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID